• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

射血分数降低的慢性心力衰竭中的药理学靶点

Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction.

作者信息

Moloce Maria-Angela, Costache Irina-Iuliana, Nicolae Ana, Onofrei Aursulesei Viviana

机构信息

Iasi "Saint Spiridon" County Hospital, 700111 Iasi, Romania.

Iasi "Saint Spiridon" County Hospital, Iasi "Grigore T. Popa" University of Medicine and Pharmacy, 700111 Iasi, Romania.

出版信息

Life (Basel). 2022 Jul 24;12(8):1112. doi: 10.3390/life12081112.

DOI:10.3390/life12081112
PMID:35892914
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9394280/
Abstract

Heart failure management has been repeatedly reviewed over time. This strategy has resulted in improved quality of life, especially in patients with heart failure with reduced ejection fraction (HFrEF). It is for this reason that new mechanisms involved in the development and progression of heart failure, along with specific therapies, have been identified. This review focuses on the most recent guidelines of therapeutic interventions, trials that explore novel therapies, and also new molecules that could improve prognosis of different HFrEF phenotypes.

摘要

随着时间的推移，心力衰竭的管理已被反复审视。这种策略已使生活质量得到改善，尤其是在射血分数降低的心力衰竭（HFrEF）患者中。正是由于这个原因，已经确定了参与心力衰竭发生和发展的新机制以及特定疗法。本综述重点关注治疗干预的最新指南、探索新疗法的试验，以及可能改善不同HFrEF表型预后的新分子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ab3/9394280/d6732700233b/life-12-01112-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ab3/9394280/35a671441b0e/life-12-01112-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ab3/9394280/baaf78bacb2c/life-12-01112-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ab3/9394280/877bdfdd3028/life-12-01112-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ab3/9394280/d6732700233b/life-12-01112-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ab3/9394280/35a671441b0e/life-12-01112-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ab3/9394280/baaf78bacb2c/life-12-01112-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ab3/9394280/877bdfdd3028/life-12-01112-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ab3/9394280/d6732700233b/life-12-01112-g004.jpg

相似文献

1
Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction.射血分数降低的慢性心力衰竭中的药理学靶点
Life (Basel). 2022 Jul 24;12(8):1112. doi: 10.3390/life12081112.
2
Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review.射血分数降低的心力衰竭的当代药物治疗：综述
Curr Cardiol Rev. 2020;16(1):55-64. doi: 10.2174/1573403X15666190709185011.
3
Sacubitril/Valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction Focusing on the Impact on the Quality of Life: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.沙库巴曲缬沙坦治疗射血分数降低的心力衰竭：聚焦对生活质量的影响——一项随机临床试验的系统评价和荟萃分析
Cureus. 2023 Nov 11;15(11):e48674. doi: 10.7759/cureus.48674. eCollection 2023 Nov.
4
Heart Failure With Preserved Ejection Fraction (HFpEF)射血分数保留的心力衰竭（HFpEF）
5
Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials.射血分数保留的心力衰竭：临床试验中实验药物的关键绊脚石。
Expert Opin Investig Drugs. 2022 May;31(5):463-474. doi: 10.1080/13543784.2022.2069009. Epub 2022 Apr 27.
6
Heart failure with non-reduced ejection fraction: Epidemiology, pathophysiology, phenotypes, diagnosis and treatment approaches.射血分数保留的心力衰竭：流行病学、病理生理学、表型、诊断及治疗方法
Turk Kardiyol Dern Ars. 2022 May;50(Supp1):S1-S34. doi: 10.5543/tkda.2022.S1.
7
New perspectives and future directions in the treatment of heart failure.心力衰竭治疗的新视角和未来方向。
Heart Fail Rev. 2020 Jan;25(1):147-159. doi: 10.1007/s10741-019-09829-7.
8
Predictors and prognostic implications of left ventricular ejection fraction trajectory improvement in the spectrum of heart failure with reduced and mildly reduced ejection fraction.射血分数降低和轻度降低的心力衰竭谱中左心室射血分数轨迹改善的预测因素及其预后意义。
J Cardiol. 2024 Apr;83(4):250-257. doi: 10.1016/j.jjcc.2023.09.012. Epub 2023 Oct 5.
9
Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort.在中国 4880 例队列中，射血分数保留、轻度降低和降低的心衰患者的 5 年死亡率。
ESC Heart Fail. 2022 Aug;9(4):2336-2347. doi: 10.1002/ehf2.13921. Epub 2022 Apr 18.
10
Myocardial expression of somatotropic axis, adrenergic signalling, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction.射血分数保留的心力衰竭和射血分数降低的心力衰竭中生长激素轴、肾上腺素能信号传导及钙处理相关基因的心肌表达
ESC Heart Fail. 2021 Apr;8(2):1681-1686. doi: 10.1002/ehf2.13067. Epub 2021 Jan 29.

引用本文的文献

1
Standardized injection for left ventricular remodeling and inflammation in patients with HFrEF: a systematic review and meta-analysis.射血分数降低的心力衰竭患者左心室重构和炎症的标准化注射治疗：一项系统评价和荟萃分析。
Front Pharmacol. 2025 Mar 3;16:1536686. doi: 10.3389/fphar.2025.1536686. eCollection 2025.

本文引用的文献

1
Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study.白细胞介素-1 阻断在近期失代偿性心力衰竭（REDHART2）中的作用机制和设计：一项随机、双盲、安慰剂对照、单中心、2 期研究。
J Transl Med. 2022 Jun 15;20(1):270. doi: 10.1186/s12967-022-03466-9.
2
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
3
Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?心力衰竭中的微量营养素缺乏：线粒体功能障碍作为共同的病理生理机制？
J Intern Med. 2022 Jun;291(6):713-731. doi: 10.1111/joim.13456. Epub 2022 Feb 9.
4
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
5
New Targets in Heart Failure Drug Therapy.心力衰竭药物治疗的新靶点
Front Cardiovasc Med. 2021 May 5;8:665797. doi: 10.3389/fcvm.2021.665797. eCollection 2021.
6
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.射血分数对 GALACTIC-HF 中接受 Omecamtiv Mecarbil 治疗的患者临床结局的影响。
J Am Coll Cardiol. 2021 Jul 13;78(2):97-108. doi: 10.1016/j.jacc.2021.04.065. Epub 2021 May 17.
7
Mechanisms and Models in Heart Failure: A Translational Approach.心力衰竭的机制与模型：转化医学方法。
Circ Res. 2021 May 14;128(10):1435-1450. doi: 10.1161/CIRCRESAHA.121.318158. Epub 2021 May 13.
8
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology.心力衰竭患者特征分析以制定个体化的医学治疗方案。欧洲心脏病学会心力衰竭协会的共识文件。
Eur J Heart Fail. 2021 Jun;23(6):872-881. doi: 10.1002/ejhf.2206. Epub 2021 May 20.
9
Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial.心力衰竭随机临床试验的实用设计：TRANSFORM-HF 试验的原理和设计。
JACC Heart Fail. 2021 May;9(5):325-335. doi: 10.1016/j.jchf.2021.01.013. Epub 2021 Mar 10.
10
In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure.小分子 APJ（阿片肽受体）激动剂 BMS-986224 的体外和体内评价，作为心力衰竭潜在治疗方法的研究。
Circ Heart Fail. 2021 Mar;14(3):e007351. doi: 10.1161/CIRCHEARTFAILURE.120.007351. Epub 2021 Mar 5.